IM Cannabis Corp. income statement

In fiscal 2025, IM Cannabis Corp. reported revenue of $39.2m, down 0.7% on the year before, operating income of −$8.3m (a -21.2% margin) and net income of −$8.1m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

IM Cannabis Corp.: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	7	12	27	42	36	39	39
Cost of revenue	4	5	20	33	28	33	32
Gross profit	3	8	5	7	7	6	7
Research and development	0	0	—	—	—	—	—
Operating income	−8	−6	−18	−24	−9	−7	−8
Interest expense	—	—	—	1	0	0	0
Income before tax	−6	−21	−0	−20	−7	−9	−8
Income tax	0	0	0	−1	1	−1	0
Net income	−5	−21	−14	−145	−7	−8	−8
Diluted EPS	—	−$14.17	−$5.35	−$124.50	−$3.30	−$3.29	—
Diluted shares (average)	3m	4m	6m	7m	13m	—	—
EBITDA	−7	−5	−17	−22	—	—	—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CPIX vs IMCC BGM vs IMCC IMCC vs SBFM BFRI vs IMCC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from IM Cannabis Corp.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to IM Cannabis Corp.